Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • AI and healthcare
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
      • Top Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • AI and healthcare
    • Industry Perspective
  • Home
  • Dermatology
  • Dermatology News
  • Low-Dose Cemiplimab...

Low-Dose Cemiplimab Injections Achieve Complete Pathological Response in Early-Stage CSCC: JAAD Study

Written By : Medha Baranwal ,Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2026-11-22T20:45:00+05:30  |  Updated On 22 Nov 2026 8:45 PM IST
Low-Dose Cemiplimab Injections Achieve Complete Pathological Response in Early-Stage CSCC: JAAD Study
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: Low-dose intralesional cemiplimab demonstrated an acceptable safety profile and promising tumour response in patients with early-stage cutaneous squamous cell carcinoma (CSCC), a phase 1 study published in the Journal of the American Academy of Dermatology has shown. The findings suggest that injecting immunotherapy directly into the tumour may offer a potential non-surgical treatment approach for selected patients with early-stage skin cancer.

The study was conducted by Michael Migden, MD, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, and colleagues.
CSCC is a common form of skin cancer, and surgical excision remains an established treatment option. However, non-surgical alternatives for patients with small, early-stage tumours measuring 1–2 cm remain limited. Cemiplimab, an immune checkpoint inhibitor targeting programmed death 1 (PD-1), has demonstrated activity against CSCC. Researchers investigated whether administering lower doses directly into the tumour could achieve tumour control while maintaining an acceptable safety profile.
The open-label, phase 1 pilot study (NCT03889912) evaluated intralesional cemiplimab through dose-escalation and expansion cohorts. A single tumour lesion was treated in each participant. During dose escalation, patients received weekly injections of 5 mg, 15 mg or 44 mg for 12 weeks. Subsequently, two expansion cohorts received 5 mg intralesional cemiplimab either weekly or once every two weeks for six weeks.
Tumour response was evaluated visually at Weeks 7 and 13, followed by surgical excision at Week 13 to assess pathological response.
The analysis revealed the following findings:
  • Study population: A total of 41 patients participated in the trial evaluating intralesional cemiplimab for early-stage CSCC.
  • Safety profile: Treatment was generally well tolerated. In both expansion cohorts, treatment-emergent adverse events were limited to Grade 1 or 2, with no higher-grade events reported.
  • Visual tumour response: At Week 13, complete visual response was achieved in 58.3% of patients receiving weekly injections in Cohort A and 41.7% of those receiving injections every two weeks in Cohort B.
  • Pathological response: Complete pathological response rates at Week 13 were 58.3% in Cohort A and 66.7% in Cohort B, indicating no detectable residual tumour in the assessed surgical specimens.
The researchers acknowledged that the limited sample size restricts the generalizability of the findings. Additionally, differences in intralesional administration could have influenced treatment delivery and response.
The investigators concluded that low-dose intralesional cemiplimab demonstrated encouraging activity and acceptable tolerability in early-stage CSCC. The findings support further investigation of the 5 mg weekly regimen as a potential non-surgical treatment strategy. Larger studies will be necessary to establish its effectiveness, safety and suitability for routine clinical practice.
Reference:
Migden, M., Ibrahim, S. F., Strasswimmer, J., Zeitouni, N., Rogers, G. S., DeSimone, J., Kheterpal, M., Visich, J. E., Han, H., Yoo, S., Seebach, F., Lowy, I., Cristea, M., & Fury, M. (2026). Intralesional cemiplimab for patients with early-stage cutaneous squamous cell carcinoma: Results from a dose-escalation study with expansion cohorts. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.10.075
Journal of the American Academy of DermatologyIntralesional immunotherapycemiplimabcutaneous squamous cell carcinoma
Source : Journal of the American Academy of Dermatology

Medical Survey

Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Print Article
    Show Full Article
    Next Story
    Recommended For You
    NO DATA FOUND

    Editorial

    Why Does Nasal Congestion Persist Despite Allergic Rhinitis Treatment? Understanding Treatment Gaps and Rebound Congestion

    Why Does Nasal Congestion Persist Despite Allergic Rhinitis Treatment? Understanding Treatment Gaps...

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev Joshi

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev...

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

    View All

    Journal Club Today

    Sun Pharma Introduces Cognitgrey, a Nutritional Supplement for Childrens Cognitive Development

    Sun Pharma Introduces Cognitgrey, a Nutritional Supplement for Children's Cognitive Development

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok